Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Coley Pharmaceutical Group

Request full access

Therapeutics and drug candidates to fight cancers, asthma, allergy and autoimmune disorders

Wellesley, United StatesFounded 1997Biotech & Life Sciences

About Coley Pharmaceutical Group

Coley Pharmaceutical Group operated as a biopharmaceutical company focused on developing a novel class of drug candidates known as TLR Therapeutics. The company was co-founded in 1997 by Dr. Arthur M. Krieg, whose earlier discovery of the immune-stimulatory CpG DNA motif in 1994 provided the scientific foundation for the firm's therapeutic approach. This technology centered on Toll-like receptors (TLRs), which are crucial components of the immune system. Coley's strategy was to create drugs that could stimulate or block these receptors to direct the immune system to combat diseases.

The company's business model was rooted in the research and development of these immunomodulatory drugs and vaccine adjuvants. It established a pipeline of product candidates targeting TLRs 7, 8, and 9, with applications aimed at cancers, allergy and asthma disorders, autoimmune diseases, and infectious diseases. Revenue generation and pipeline advancement were pursued through strategic partnerships and license agreements with major pharmaceutical corporations, including Pfizer, sanofi-aventis, GlaxoSmithKline, and Merck. Before its acquisition, the company had raised at least $55 million in funding from investors such as Venrock and Carlyle AlpInvest.

A significant milestone in the company's history was the acquisition of the majority of 3M's therapeutic TLR cancer programs in June 2007. This deal expanded Coley's intellectual property, adding a portfolio of small molecule candidates targeting TLR7 and TLR8. However, a major setback occurred that same year when Pfizer, a key partner, discontinued development of a promising lung cancer compound, PF-3512676, after Phase III trials showed a lack of additional efficacy. Despite this, Pfizer proceeded to acquire Coley Pharmaceutical Group in a deal announced in November 2007 for an enterprise value of $164 million. The acquisition was completed in early 2008, integrating Coley's technology and pipeline into Pfizer's vaccine and immunotherapeutics strategy.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
1997
Headquarters
Wellesley, United States
Employees
8
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2007 $164M $164M Pfizer —
DEBTDebt Feb 2007 $0 — Thuja Capital —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Coley Pharmaceutical Group website traffic

Latest recorded traffic for Coley Pharmaceutical Group is 0 monthly website visits. Coley Pharmaceutical Group's team declined 11.1% over the past year.

Latest monthly visits0 1-year team growth-11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Coley Pharmaceutical Group in the Wellesley ecosystem

Live from Dealroom

The Coley Pharmaceutical Group office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Techno Venture Management
  • Alafi Capital
  • Qiagen

Series B and later4 investors entered at this stage

  • Thomas McNerney & Partners
  • Venrock
  • Thuja Capital
  • Global Life Science Ventures

Other known investors1 additional known investor

  • Pfizer
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany50%
🇨🇦 Canada50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Coley Pharmaceutical Group on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Coley Pharmaceutical Group’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.